0001193125-15-344325.txt : 20151015 0001193125-15-344325.hdr.sgml : 20151015 20151015093859 ACCESSION NUMBER: 0001193125-15-344325 CONFORMED SUBMISSION TYPE: SC TO-T/A PUBLIC DOCUMENT COUNT: 4 FILED AS OF DATE: 20151015 DATE AS OF CHANGE: 20151015 GROUP MEMBERS: BLUE SUBSIDIARY CORP. GROUP MEMBERS: VALEANT PHARMACEUTICALS INTERNATIONAL SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: SYNERGETICS USA INC CENTRAL INDEX KEY: 0000836429 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 205715943 FISCAL YEAR END: 0731 FILING VALUES: FORM TYPE: SC TO-T/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-44538 FILM NUMBER: 151159345 BUSINESS ADDRESS: STREET 1: 3845 CORPORATE CENTRE DRIVE CITY: O'FALLON STATE: MO ZIP: 63368 BUSINESS PHONE: 636-939-5100 MAIL ADDRESS: STREET 1: 3845 CORPORATE CENTRE DRIVE CITY: O'FALLON STATE: MO ZIP: 63368 FORMER COMPANY: FORMER CONFORMED NAME: VALLEY FORGE SCIENTIFIC CORP DATE OF NAME CHANGE: 19920703 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Valeant Pharmaceuticals International, Inc. CENTRAL INDEX KEY: 0000885590 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC TO-T/A BUSINESS ADDRESS: STREET 1: 2150 ST. ELZEAR BLVD. WEST STREET 2: LAVAL CITY: QUEBEC STATE: A8 ZIP: H7L 4A8 BUSINESS PHONE: 514-744-6792 MAIL ADDRESS: STREET 1: 2150 ST. ELZEAR BLVD. WEST STREET 2: LAVAL CITY: QUEBEC STATE: A8 ZIP: H7L 4A8 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL Corp DATE OF NAME CHANGE: 20100416 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL CORP INTERNATIONAL DATE OF NAME CHANGE: 19960522 SC TO-T/A 1 d88702dsctota.htm SC TO-T/A SC TO-T/A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE TO

Tender Offer Statement under Section 14(d)(1) or 13(e)(1)

of the Securities Exchange Act of 1934

(Amendment No. 7)

 

 

SYNERGETICS USA, INC.

(Name of Subject Company)

Blue Subsidiary Corp.

(Offeror)

a wholly owned subsidiary of

Valeant Pharmaceuticals International

(Offeror)

a wholly owned subsidiary of

Valeant Pharmaceuticals International, Inc.

(Parent of Offeror)

(Names of Filing Persons)

 

 

COMMON STOCK, PAR VALUE $0.001 PER SHARE

(Title of Class of Securities)

87160 G 107

(CUSIP Number of Class of Securities)

Robert Chai-Onn

Executive Vice President, General Counsel and Chief Legal Officer,

Head of Corporate and Business Development

Valeant Pharmaceuticals International, Inc.

2150 St. Elzéar Blvd. West

Laval, Quebec

Canada, H7L 4A8

(949) 461-6000

(Name, address, and telephone number of person authorized to receive notices and communications on behalf of filing persons)

 

 

With copies to:

Stephen F. Arcano

Marie L. Gibson

Skadden, Arps, Slate, Meagher & Flom LLP

4 Times Square

New York, NY 10036

(212) 735-3000

 

 

CALCULATION OF FILING FEE

 

Transaction Valuation(1)   Amount Of Filing Fee(2)
$197,790,120.00   $22,983.21
 
(1) Estimated solely for purposes of calculating the filing fee. The transaction value was determined by multiplying (x) the offer price of $6.50 net per share in cash and up to $1.00 per share in contingent cash consideration payments by the sum of (i) 25,303,474 outstanding shares of common stock, par value $0.001 per share (“Shares”) of Synergetics USA, Inc. (“Synergetics”) plus (ii) 1,068,542, the number of shares issuable upon exercise of outstanding options to acquire Shares. The calculation of the filing fee is based on information provided by Synergetics as of September 11, 2015.

 

(2) The filing fee was calculated in accordance with Rule 0-11 under the Securities Exchange Act of 1934, as amended, and Fee Rate Advisory #1 for fiscal year 2015, issued August 29, 2014 by multiplying the transaction value by .0001162.

 

x  Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

 

Amount Previously Paid: $22,983.21   Filing Party: Valeant Pharmaceuticals International, Inc., Valeant Pharmaceuticals International and Blue Subsidiary Corp.
Form or Registration No.: Schedule TO   Date Filed: September 16, 2015

 

¨  Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

 

  x  third-party tender offer subject to Rule 14d-1.
  ¨  issuer tender offer subject to Rule 13e-4.
  ¨  going-private transaction subject to Rule 13e-3.
  ¨  amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer:  ¨

If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

 

  ¨  Rule 13e-4(i) (Cross-Border Issuer Tender Offer)
  ¨  Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)

 

 

 

This Amendment No. 7 (this “Amendment”) amends and supplements the Tender Offer Statement on Schedule TO filed by Valeant Pharmaceuticals International, Inc., a Canadian corporation (“Valeant”), Valeant Pharmaceuticals International, a Delaware corporation (“VPI”) and Blue Subsidiary Corp., a Delaware corporation and a wholly owned subsidiary of VPI (the “Purchaser”) with the Securities and Exchange Commission on September 16, 2015 (as amended from time to time, the “Schedule TO”), and relates to the offer by the Purchaser to purchase all outstanding Shares, at a price of $6.50 per Share, net to the holder in cash (less any applicable withholding taxes and without interest), plus one contractual contingent value right per Share, which represents the right to receive up to two contingent payments, if any, of up to $1.00 in the aggregate net to the holder in cash (less any applicable withholding taxes and without interest) upon the achievement of certain specified milestones within an agreed upon time period, at the times and upon the terms and subject to the conditions described in the Offer to Purchase dated September 16, 2015 (together with any amendments or supplements thereto, the “Offer to Purchase”) and in the related Letter of Transmittal (together with any amendments or supplements thereto and with the Offer to Purchase, the “Offer”), which are filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively.

Capitalized terms used, but not otherwise defined, in this Amendment shall have the meanings ascribed to them in the Schedule TO. Except to the extent specifically provided in this Amendment, the information set forth in the Schedule TO remains unchanged and is incorporated herein by reference as relevant to the items in this Amendment.

ITEMS 1 through 9 and 11.

Items 1 through 9 and Item 11 of the Schedule TO are hereby amended and supplemented as follows:

“At 11:59 p.m., New York City time, on Wednesday, October 14, 2015 (the “Expiration Time”), the Offer expired as scheduled and was not extended. American Stock Transfer & Trust Company, LLC, the depositary for the Offer (the “Depositary”) has advised VPI and the Purchaser that, as of the Expiration Time, a total of 18,271,479 Shares (excluding Shares with respect to which Notices of Guaranteed Delivery were delivered but the Shares represented thereby were not yet delivered) had been validly tendered into and not properly withdrawn pursuant to the Offer, representing approximately 72.1% of the outstanding Shares as of the Expiration Time. Additionally, the Depositary has advised VPI and the Purchaser that Notices of Guaranteed Delivery have been delivered with respect to an additional 2,978,556 Shares, representing approximately 11.8% of the outstanding Shares as of the Expiration Time.

The number of Shares validly tendered and not withdrawn pursuant to the Offer satisfied the Minimum Tender Condition (as defined in the Offer to Purchase). All conditions to the Offer having been satisfied or waived, the Purchaser irrevocably accepted for payment, and expects to promptly pay for, all Shares validly tendered into and not properly withdrawn from the Offer.

Following the purchase of Shares in the Offer, the Purchaser has sufficient voting power to approve the Merger (as defined in the Offer to Purchase) without the affirmative vote of the stockholders of Synergetics in accordance with Section 251(h) of the General Corporation Law of the State of Delaware (the “DGCL”). Accordingly, and subject to the satisfaction of the remaining conditions set forth in the Merger Agreement (as defined in the Offer to Purchase), the Purchaser and VPI intend to complete the acquisition of Synergetics by consummating the Merger today in accordance with the terms of the Merger Agreement and without a vote by the stockholders of Synergetics in accordance with Section 251(h) of the DGCL. No other action by the stockholders of Synergetics will be required pursuant to Delaware law or otherwise. As a result of the Merger, at the effective time of the Merger (the “Effective Time”), each Share issued and outstanding immediately prior to the Effective Time (other than (i) any Shares held in the treasury of Synergetics and each Share owned by the Purchaser, VPI or any direct or indirect wholly owned subsidiary of VPI or by Synergetics immediately prior to the Effective Time, which will be canceled without any conversion thereof and no payment or distribution will be made with respect thereto, and (ii) any Shares owned by Synergetics’ stockholders who perfect their appraisal rights under Section 262 of the DGCL) will be canceled and will be converted automatically into the right to receive the Offer Price (as defined in the Offer to Purchase) payable, without interest, to the holder of such Share, upon surrender of the certificate that formerly evidenced such Share or, with respect to uncertificated Shares, upon the receipt by the Depositary of an Agent’s Message related to such Shares. All Shares that are converted into the right to receive the Offer Price will be canceled and cease to exist. Following consummation of the Merger, all Shares will be delisted and will cease to trade on the NASDAQ Capital Market. VPI and the Purchaser intend to take steps to cause the termination of the registration of the Shares under the Securities Exchange Act of 1934 (the “Exchange Act”) and to suspend all of Synergetics’ reporting obligations under the Exchange Act as promptly as practicable.

 

2

On October 15, 2015, Valeant issued a press release announcing the expiration and results of the Offer. The full text of the press release is attached as Exhibit (a)(5)(G) to the Schedule TO and is incorporated herein by reference.”

 

ITEM 12. EXHIBITS

Item 12 of the Schedule TO is hereby amended and supplemented to add the following exhibit:

(a)(5)(G) Press Release issued by Valeant Pharmaceuticals International, Inc. on October 15, 2015.

 

3

SIGNATURE

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: October 15, 2015

 

BLUE SUBSIDIARY CORP.

By:

  

/s/ Robert Chai-Onn

Name:   Robert Chai-Onn
Title:   Executive Vice President, General Counsel and Corporate Secretary

VALEANT PHARMACEUTICALS INTERNATIONAL

By:  

/s/ Robert Chai-Onn

Name:   Robert Chai-Onn
Title:   Executive Vice President, General Counsel and Corporate Secretary

VALEANT PHARMACEUTICALS INTERNATIONAL, INC.

By:  

/s/ Robert Chai-Onn

Name:   Robert Chai-Onn
Title:   Executive Vice President, General Counsel and Chief Legal Counsel, Head of Corporate and Business Development

 

4

EXHIBIT INDEX

 

(a)(1)(A)

   Offer to Purchase, dated September 16, 2015*

(a)(1)(B)

   Form of Letter of Transmittal (including Guidelines for Certification of Taxpayer Identification Number on Substitute Form W-9)*

(a)(1)(C)

   Form of Notice of Guaranteed Delivery*

(a)(1)(D)

   Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees*

(a)(1)(E)

   Form of Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees*

(a)(1)(F)

   Form of Summary Advertisement, published September 16, 2015 in The New York Times*

(a)(1)(G)

   Contingent Value Rights Agreement, dated as of September 16, 2015, by and between VPI and American Stock Transfer & Trust Company, LLC*

(a)(2)

   Not applicable

(a)(3)

   Not applicable

(a)(4)

   Not applicable

(a)(5)(A)

   Press Release of Valeant, dated September 2, 2015 (incorporated by reference to Exhibit (a)(5)(A) to the Schedule to Tender Offer Statement filed by Valeant with the Securities and Exchange Commission on September 2, 2015)

(a)(5)(B)

  

Section 262 of the General Corporation Law of the State of Delaware (incorporated by reference to Annex B to the

Schedule 14D-9 filed by Synergetics with the Securities and Exchange Commission on September 16, 2015)

(a)(5)(C)

   Email to employees of Synergetics USA, Inc., dated September 2, 2015 (incorporated by reference to the Solicitation/Recommendation Statement on Schedule 14D-9-C of Synergetics USA, Inc. filed with the SEC on September 4, 2015 (the “Schedule 14D-9-C”)

(a)(5)(D))

   Article published by the St. Louis Post-Dispatch, dated September 2, 2015 (incorporated by reference to the Schedule 14D-9-C).

(a)(5)(E)

   Article published by the St. Louis Business Journal, dated September 4, 2015 (incorporated by reference to the Schedule 14D-9-C).

(a)(5)(F)

   Press Release issued by Valeant Pharmaceuticals International, Inc. on October 5, 2015 (incorporated by reference to Exhibit (a)(5)(F) to Amendment No. 5 to the Schedule TO filed by the Purchaser, VPI and Valeant with the Securities and Exchange Commission on October 5, 2015)

(a)(5)(G)

   Press Release issued by Valeant Pharmaceuticals International, Inc. on October 15, 2015.

(b)

   Not applicable

(d)(1)

  

Agreement and Plan of Merger, dated September 1, 2015, by and among VPI, Purchaser, and Synergetics (incorporated by reference to Exhibit 2.1 to the Form 8-K filed by Synergetics with the Securities and Exchange Commission on

September 2, 2015)

(d)(2)

   Tender Agreement, dated as of September 1, 2015, among VPI, the Purchaser and Lawrence C. Cardinale*

(d)(3)

   Tender Agreement, dated as of September 1, 2015, among VPI, the Purchaser and Michael Fanning*

(d)(4)

   Tender Agreement, dated as of September 1, 2015, among VPI, the Purchaser and D. Graeme Thomas*

(d)(5)

   Tender Agreement, dated as of September 1, 2015, among VPI, the Purchaser and Juanita H. Hinshaw*

(d)(6)

   Tender Agreement, dated as of September 1, 2015, among VPI, the Purchaser and Pamela Boone*

(d)(7)

   Tender Agreement, dated as of September 1, 2015, among VPI, the Purchaser and Jason Stroisch*

(d)(8)

   Tender Agreement, dated as of September 1, 2015, among VPI, the Purchaser and David M. Hable*

(d)(9)

   Tender Agreement, dated as of September 1, 2015, among VPI, the Purchaser and Robert H. Blankemeyer*

(d)(10)

   Exclusivity Agreement by and between Synergetics and Valeant dated August 19, 2015 (incorporated by reference to Exhibit (e)(4) to the Schedule 14D-9 filed by Synergetics with the Securities and Exchange Commission on September 16, 2015)

(d)(11)

   Confidentiality Agreement by and between Synergetics and Valeant, dated January 6, 2015 (incorporated by reference to Exhibit (e)(3) to the Schedule 14D-9 filed by Synergetics with the Securities and Exchange Commission on September 16, 2015)

(g)

   Not applicable

(h)

   Not applicable

 

* Previously filed with the Tender Offer Statement on Schedule TO filed by the Purchaser, VPI and Valeant with the Securities and Exchange Commission on September 16, 2015.

 

5

EX-99.(A)(5)(G) 2 d88702dex99a5g.htm EX-(A)(5)(G) EX-(a)(5)(G)

Exhibit (a)(5)(G)

 

LOGO

International Headquarters

2150 St. Elzéar Blvd. West

Laval, Quebec H7L 4A8

Phone: 514.744.6792

Fax: 514.744.6272

Contact Information:

Laurie W. Little

949-461-6002

laurie.little@valeant.com

Elif McDonald

905-695-7607

elif.mcdonald@valeant.com

VALEANT PHARMACEUTICALS INTERNATIONAL, INC. COMPLETES

TENDER OFFER FOR SYNERGETICS USA, INC.

Laval, Quebec, October 15, 2015 - Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) (“Valeant”) today announced the expiration of the tender offer (the “Offer”) by a subsidiary of Valeant Pharmaceuticals International (“VPI”) to purchase all of the outstanding shares of Synergetics USA, Inc. (NASDAQ: SURG) (“Synergetics”), at a price per share of $6.50, net to the holder in cash (less any applicable withholding taxes and without interest), plus one contractual contingent value right (“CVR”) per share, which represents the right to receive up to two contingent payments, if any, of up to $1.00 in the aggregate net to the holder in cash (less any applicable withholding taxes and without interest) upon the achievement of certain specified milestones.

The Offer expired at 11:59 p.m. New York City time, on October 14, 2015. American Stock Transfer & Trust Company, LLC, the depositary for the tender offer, has advised that, as of the expiration of the Offer, a total of 18,271,479 shares had been tendered into and not withdrawn from the Offer, representing approximately 72.1% of Synergetics’ outstanding shares. Additionally, the depositary has advised that an additional 2,978,556 shares had been tendered by notice of guaranteed delivery, representing approximately 11.8% of Synergetics’ outstanding shares. The condition to the Offer that at least a majority of the outstanding shares of Synergetics common stock (on a fully diluted basis), not including shares tendered pursuant to procedures for guaranteed delivery and not yet delivered, be validly tendered and not properly withdrawn prior to the expiration of the Offer has been satisfied. Accordingly, all shares that were validly tendered and not properly withdrawn were accepted for payment and Valeant will promptly pay for all such tendered shares in accordance with the terms of the Offer. As a result of the tenders, Valeant will own a majority of the outstanding Synergetics shares (on a fully diluted basis), not including shares tendered pursuant to procedures for guaranteed delivery and not yet delivered, and expects to complete today the acquisition of Synergetics through a merger without a vote of Synergetics stockholders pursuant to Section 251(h) of the Delaware General Corporation Law.

LOGO

 

As a result of the merger, Synergetics will become a wholly owned subsidiary of VPI. In the merger, each remaining share of Synergetics that was not validly tendered in the Offer will be cancelled and converted into the right to receive the same price per share of $6.50 in cash (less any applicable withholding taxes and without interest) and one CVR, each without interest and less any applicable withholding taxes that was paid in the Offer. Following completion of the merger, the common stock of Synergetics will no longer be listed for trading on the NASDAQ Capital Market, which is expected to take effect as of the close of the market today.

About Valeant Pharmaceuticals International, Inc.

Valeant is a multinational, specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products and medical devices primarily in the areas of dermatology, gastrointestinal disorder, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.

Forward Looking Statements

This press release may contain forward-looking statements, including, but not limited to, the consummation of the acquisition of Synergetics. Forward-looking statements may generally be identified by the use of the words “anticipates,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” “target” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in our most recent annual and quarterly reports and detailed from time to time in our other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which risks and uncertainties are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. We undertake no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes, except as required by law.

###

GRAPHIC 3 g88702g09c75.jpg GRAPHIC begin 644 g88702g09c75.jpg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end GRAPHIC 4 g88702g40p53.jpg GRAPHIC begin 644 g88702g40p53.jpg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end